ArticleAntimicrobial agents and chemotherapy2014
Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections.
Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 128 citations in OpenAlex.
- Are two really better than one? A retrospective study comparing monotherapy versus combination therapy forMicrobiology spectrum · 2026Article
- Efficacy of cefiderocol and levofloxacin againstAntimicrobial agents and chemotherapy · 2026Article
- Article
- Article
- Clinical Outcomes of Eravacycline in Patients Treated for Stenotrophomonas maltophilia Infections.Infectious diseases and therapy · 2025Article
- Cefiderocol for the Treatment of Nosocomial Bloodstream Infections Caused by Stenotrophomonas maltophilia: A Case Series and Literature Review.Infectious diseases and therapy · 2025Article
- Low- versus high-dose trimethoprim-sulfamethoxazole for the treatment ofAntimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Review
- Clinical Outcomes of Trimethoprim/Sulfamethoxazole in Critically Ill Patients withJournal of clinical medicine · 2024Article
- Stenotrophomonas maltophilia: An Urgent Threat with Increasing Antibiotic Resistance.Current microbiology · 2023Review
- Article
- Risk factors and outcome of Stenotrophomonas maltophilia infection after allogeneic hematopoietic stem cell transplantation: JSTCT, Transplant Complications Working Group.Annals of hematology · 2023Article
- Review
- Molecular Epidemiology ofOman medical journal · 2023Article
- Association between minimum inhibitory concentration values and mortality risk in patients withJAC-antimicrobial resistance · 2023Article
- The Prognosis of Patients Tested Positive forInfection and drug resistance · 2023Article
- Endotracheal Aspirate and Ventilator-Associated Pneumonia in Neonates: Revisiting an Age-Old Debate.Indian journal of pediatrics · 2022Article
- Stenotrophomonas maltophilia Infection Associated with COVID-19: A Case Series and Literature Review.The American journal of case reports · 2022Review
- Clinical challenges treatingJAC-antimicrobial resistance · 2022Review
- Clinical Characteristics, Outcomes, and Risk Factors for Mortality in Patients withJournal of clinical medicine · 2022Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of choice for Stenotrophomonas maltophilia is trimethoprim-sulfamethoxazole (SXT). Fluoroquinolones (FQs) have in vitro activity against S. maltophilia; however, there is limited published information on their effectiveness. The purpose of this study is to compare the effectiveness of FQs and SXT for the treatment of S. maltophilia. A retrospective review of 98 patients with S. maltophilia infections who received SXT or FQ monotherapy was conducted. Patients ≥18 years old with a positive culture for S. maltophilia and clinical signs of infection who received treatment for ≥48 h were included. Microbiological cure and clinical response were evaluated at the end of therapy (EOT). In-hospital mortality and isolation of nonsusceptible isolates were also evaluated. Thirty-five patients received SXT, and 63 patients received FQ; 48 patients received levofloxacin, and 15 patients received ciprofloxacin. The most common infection was pulmonary. The overall microbiological cure rate at EOT was 63%. Thirteen of 20 patients (65%) who received SXT and 23 of 37 patients (62%) who received FQ had microbiological cure at EOT (P = 0.832). The overall clinical success rate was 55%, 52% for those who received FQ and 61% for those who received SXT (P = 0.451). In-hospital mortality was 24%, with similar rates in the two groups (25% for FQ versus 22% for SXT; P = 0.546). Development of resistance on repeat culture was 30% for FQ and 20% for SXT (P = 0.426). Fluoroquinolone and SXT monotherapies may be equally effective for the treatment of S. maltophilia infections. Resistance was documented in subsequent isolates of S. maltophilia in both groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.